Full-Time

Security Operations Manager

Updated on 9/3/2026

LUX Infusion

LUX Infusion

1-10 employees

Outpatient infusion centers for IV therapies

Compensation Overview

$115k - $135k/yr

United States

In Person

Bachelor's

Category
Cybersecurity (1)
Required Skills
Microsoft Azure
Incident Response
Data Visualization
Cybersecurity
Vulnerability Analysis
Role-based Access Control
SAML
HIPAA
OAuth

Get referred to LUX Infusion

See people who can refer or advise you

Requirements
  • A Bachelor's Degree in Cybersecurity, Information Technology, Computer Science, or a related field, or equivalent experience.
  • At least 7 years of progressive cybersecurity experience.
  • At least 3 years of experience leading security operations or security engineering initiatives.
  • Experience within healthcare, specialty pharmacy, or another highly regulated industry.
  • Hands-on experience implementing and administering enterprise Single Sign-On and Identity and Access Management platforms.
  • Strong experience with Microsoft Entra ID (Azure AD), Single Sign-On using SAML, OIDC, and OAuth, Multi-Factor Authentication, SIEM platforms, EDR/XDR technologies, vulnerability management, and security incident response.
  • Experience supporting HIPAA compliance and healthcare security assessments.
Responsibilities
  • Lead and manage Security Operations activities across infrastructure, applications, cloud platforms, and endpoints.
  • Develop and maintain security monitoring, threat detection, incident response, and security governance processes.
  • Serve as the primary escalation point for complex security incidents and investigations.
  • Direct security event analysis, triage, containment, eradication, and recovery activities.
  • Establish operational metrics, dashboards, and KPIs to measure security effectiveness.
  • Drive continuous improvement initiatives to enhance enterprise cybersecurity maturity.
  • Coordinate security activities with managed security service providers and strategic security partners.
  • Lead enterprise Identity and Access Management strategy and implementation.
  • Design, implement, and maintain Single Sign-On platforms and identity federation technologies.
  • Manage security controls related to Azure AD/Entra ID, Multi-Factor Authentication, conditional access, role-based access control, and privileged access management.
  • Partner with application owners to onboard business-critical applications into Single Sign-On platforms.
  • Establish identity governance processes, user lifecycle management standards, and access review programs.
  • Conduct identity risk assessments and develop remediation plans.
  • Oversee authentication modernization initiatives and Zero Trust security models.
  • Ensure compliance with HIPAA, HITECH, HITRUST, NIST Cybersecurity Framework, and healthcare cybersecurity best practices.
  • Lead security risk assessments and remediation planning.
  • Support internal and external audits.
  • Develop and maintain healthcare-focused security policies, standards, and procedures.
  • Monitor controls protecting Protected Health Information and electronic Protected Health Information.
  • Collaborate with Compliance, Legal, and Operations teams on security and privacy matters.
  • Participate in breach investigations, reporting requirements, and corrective action programs.
  • Oversee SIEM, EDR, vulnerability management, email security, and threat intelligence platforms.
  • Direct proactive threat hunting activities.
  • Lead cyber incident response exercises and tabletop simulations.
  • Manage forensic investigations and root-cause analysis efforts.
  • Coordinate post-incident reviews and remediation planning.
  • Maintain incident response playbooks and operational procedures.
  • Direct vulnerability management programs across servers, endpoints, cloud environments, and applications.
  • Establish risk-based prioritization methodologies for remediation.
  • Oversee remediation tracking and reporting.
  • Evaluate new technologies, vendors, and cloud services for cybersecurity risk.
  • Conduct third-party security assessments and vendor reviews.
  • Supervise, coach, and mentor Security Analysts and junior cybersecurity staff.
  • Develop career growth plans, training programs, and technical development pathways.
  • Conduct regular one-on-one meetings and performance coaching.
  • Provide guidance on incident investigations, technical analysis, and security operations best practices.
  • Foster a collaborative culture focused on continuous learning and operational excellence.
  • Create succession planning and cross-training opportunities within the security team.
  • Participate in recruiting, interviewing, onboarding, and workforce planning activities.
  • Promote cybersecurity awareness throughout the organization.
  • Deliver technical and non-technical security presentations.
  • Partner with Infrastructure, Application Development, Service Desk, and Compliance teams on security initiatives.
Desired Qualifications
  • CISSP certification.
  • HCISPP certification.
  • CISM certification.
  • GIAC certifications.
  • Microsoft Identity & Access Administrator Certification.
  • HITRUST experience.
  • Healthcare cybersecurity leadership experience.

LUX Infusion provides ambulatory infusion services in Alaska, delivering IV and injectable therapies outside hospital settings in spa-like centers in Anchorage, Palmer, and Fairbanks. A clinical team of physicians, nurse practitioners, and infusion nurses collaborates with referring providers, while centers handle pre-authorizations and financial assistance, serving patients with private insurance, Medicare, and Medicaid. In 2025, LUX Infusion was acquired by BioMatrix Infusion Pharmacy, integrating its care teams into a national ambulatory infusion network to expand the Pacific Northwest and accelerate growth; the company holds NICA accreditation and the AICE-Ambulatory Infusion Center of Excellence designation. Its goal is to provide high-quality, patient-centered outpatient infusion care that reduces medical costs and offers an alternative to hospital-based treatment.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

Anchorage, Alaska

Founded

2022

Get referred to LUX Infusion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 Infuse IQ acquisition adds Wyoming sites and widens referral reach.
  • May 28, 2026 promotion of Dan Teich strengthens market-access negotiations with payors and manufacturers.
  • Home infusion plus ambulatory care creates cross-referral opportunities and more therapy starts than hospital sites.

What critics are saying

  • Biomatrix integration can standardize LUX away, erasing local brand distinction by 2027.
  • Infuse IQ’s August 6, 2026 acquisition stretches management and capital across Wyoming and Alaska.
  • Specialty infusion reimbursement pressure from payors and manufacturers can compress margins if contracts reset in 2027.

What makes LUX Infusion unique

  • Alaska’s only scaled ambulatory infusion footprint in Anchorage, Palmer, and Fairbanks anchors local density.
  • Clinician-led, spa-like infusion centers with NICA and AICE designations signal differentiated patient experience.
  • BioMatrix acquired LUX on October 17, 2025, plugging it into national specialty-infusion infrastructure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Company News

Access Market Intelligence
Aug 30th, 2026
Specialty Pharmacy news roundup: august 2026.

Specialty Pharmacy news roundup: august 2026. The following are just a few of the many recent specialty pharmacy activities during the past month. Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Cycle Pharmaceuticals as a limited distribution specialty pharmacy provider for CAVHANZA (nilotinib) Orally Disintegrating Tablets. CAVHANZA is a tyrosine kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and/or adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. Biologics by McKesson has also been selected by Revolution Medicines as a specialty pharmacy provider for RASONQUE (daraxonrasib) within its distribution network. RASONQUE is an oral therapy approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Carepoint Pharmacy, an end-to-end access hub and dispensing pharmacy serving patients nationwide, announced a new partnership with and investment from New Heritage Capital, a Boston-based private equity firm focused on partnering with high-growth, founder-owned businesses. The investment was structured using Heritage's Private IPO solution, which leaves operating control in the hands of current Carepoint management while providing the financial flexibility to accelerate future growth. LUX Infusion, a clinician-led infusion services company, announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered independent infusion therapy provider delivering safe, personalized infusion and injection treatments across a broad range of medical specialties. The acquisition expands LUX Infusion's ambulatory infusion network and strengthens its ability to serve patients and referring providers in communities across the country. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), which is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Onco360 has also been selected as a pharmacy partner by Revolution Medicines for RASONQUE (daraxonrasib), which is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. PANTHERx Rare has been selected by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., as the exclusive U.S. specialty pharmacy partner to distribute LYNAVOY (linerixibat), the first FDA-approved treatment specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This collaboration underscores the company's commitment to innovative rare disease care and its mission to reduce barriers for patients facing complex conditions. PANTHERx Rare has also been selected by Vera Therapeutics, Inc. to dispense TRUTAKNA (atacicept-vymj), an FDA-approved treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. IgAN is a complex, progressive kidney disease, and timely access to treatment can make a meaningful difference. The company's team is committed to helping patients navigate access, stay on therapy, and receive personalized support every step of the way. You can find even more news and insights by subscribing to AMI's Specialty Pharmacy Database. Keep up with accreditations earned, key decision-maker changes, mergers and acquisitions and MORE.

PR Newswire
Aug 6th, 2026
LUX Infusion Acquires Infuse IQ, Expanding Its National Ambulatory Infusion Footprint

/PRNewswire/ -- LUX Infusion, a clinician-led infusion services company, today announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered...

LUX Infusion
May 28th, 2026
LUX Infusion promotes Dan Teich to Senior Vice President, Market Access.

LUX Infusion promotes Dan Teich to Senior Vice President, Market Access. Unified leadership role aligns trade relations and managed care to strengthen distribution, manufacturer, and payor partnerships. [Plantation, FL] - May 28, 2026 - LUX Infusion, a U.S.-based, clinician-led infusion services company, today announced the promotion of Dan Teich to Senior Vice President, Market Access. In this expanded role, Teich will lead a unified market access function that brings together the company's trade relations and managed care operations under a single, cohesive strategy designed to deepen alignment with LUX Infusion's distribution, manufacturer, and payor partners. "Dan has been an exceptional leader in shaping our trade relationships, and this promotion reflects both his contributions and our confidence in his vision," said Ted Kramm, Chief Executive Officer of LUX Infusion. "By unifying trade relations and managed care under his leadership, we are creating a more integrated approach to how we work with our partners, positioning LUX Infusion to deliver greater value across the entire specialty infusion ecosystem." As SVP, Market Access, Teich will be responsible for developing and executing a comprehensive strategy that aligns the company's market access partnerships across pharmaceutical manufacturers, specialty distributors, group purchasing organizations, and health plan payors with LUX Infusion's mission to expand patient access to high-quality, accessible infusion care. Teich brings more than 15 years of expertise in pharmacy operations, supply chain management, contract negotiation, and executive leadership across the specialty infusion, health system, and retail pharmacy sectors. Prior to joining LUX Infusion, he served as Vice President of Health Systems Manufacturer Relations at Cencora (formerly AmerisourceBergen), where he led negotiations of specialty and biosimilar GPO contracts for health systems, consistently exceeding fiscal-year performance targets. Before Cencora, Teich served as Vice President of Pharmacy Purchasing and Contracting at M Health Fairview, overseeing nearly $1 billion in annual drug spend and driving significant margin improvements through strategic contracting. As Program Manager of Home Infusion and Compounding at the same organization, he grew home infusion revenue by more than 240% over four years. He also held leadership roles at PharMerica and Walgreens. Teich holds a Doctor of Pharmacy (Pharm.D.) from North Dakota State University and has been a licensed pharmacist in Minnesota since 2007. "The convergence of trade relations and managed care under a unified market access function is a natural evolution for LUX Infusion as we scale nationally," said Teich. "I'm energized by the opportunity to work even more closely with our manufacturer, distribution, and payor partners to remove barriers and ensure patients receive the therapies they need, when and where they need them." This leadership structure reflects LUX Infusion's broader commitment to building a fully integrated infusion services platform that leverages strong partner relationships to drive superior clinical outcomes, operational efficiency, and expanded patient access as the company continues its growth toward more than 50 infusion locations nationwide. About LUX Infusion. LUX Infusion is elevating infusions into an experience. As a U.S. based, clinician-led infusion services company, it provides both home infusion and ambulatory infusion center services, bringing clarity, compassion, and expertise to every patient relationship. With faster therapy starts, dedicated patient support, and continuous data sharing with providers, LUX Infusion ensures patients feel supported, and providers and partners can trust in better adherence and outcomes. Media Contact: Tara Marchese Senior Director of Marketing, LUX Infusion Tel: 954-908-7636 Email: [email protected]

PR Newswire
Oct 20th, 2025
BioMatrix Infusion Pharmacy Closes Acquisition of LUX Infusion, Expanding National Ambulatory Infusion Footprint

PLANTATION, Fla., Oct. 20, 2025 /PRNewswire/ -- BioMatrix Infusion Pharmacy today announced the successful acquisition of LUX Infusion, Alaska's premier ambulatory infusion center business, effective October 17, 2025. LUX operates three state-of-the-art infusion centers across Alaska, delivering high-quality, patient-centered care and earning a strong reputation for clinical excellence and trusted provider and payer partnerships."Our decision to acquire LUX Infusion is rooted in a shared commitment to advancing access, quality, and innovation in ambulatory infusion care," said Ted Kramm, Chief Executive Officer, BioMatrix Infusion Pharmacy. "Together, we are better positioned to transform infusion care delivery and ensure that patients nationwide receive the highest standard of treatment.""We founded LUX to deliver clinical excellence in a setting of comfort and convenience. Proving this model in Alaska, while lowering costs for complex treatments, exceeded our expectations," said Lisa Bruce, Co-Founder of LUX Infusion. "Partnering with BioMatrix strengthens our commitment and allows us to expand this model nationwide, raising the standard of outpatient infusion care with partners who share our vision and values."Strategic Benefits of the AcquisitionThrough the integration of LUX Infusion, BioMatrix strengthens its national platform in several key ways:Expand Our Reach: Adds three premier infusion centers in Alaska, advancing BioMatrix's ability to serve patients in key growth markets and meet the rising demand for infusion services.Enhance Clinical Capabilities: Integrates LUX's highly skilled care teams and proven operating model into BioMatrix's growing nationwide network.Accelerate Growth & Innovation: Combines resources to scale new infusion sites more efficiently and deliver expanded therapy options.Expand Home Infusion Nursing: Extends BioMatrix's home infusion nursing capabilities into the Pacific Northwest, providing greater flexibility and access for patients who prefer care in the home setting.Deliver Greater Value: Improves access, outcomes, and experiences for patients while deepening partnerships with providers and payers.LUX Infusion has recently received NICA accreditation and designation of AICE-Ambulatory Infusion Center of Excellence, which reflects their unwavering commitment to delivering safe, high-quality and value-based infusion care.With this acquisition, BioMatrix continues to evolve into one of the nation's most comprehensive infusion pharmacy providers—extending its reach into the Pacific Northwest and reinforcing its commitment to delivering best-in-class care for complex and chronic conditions.About BioMatrix Infusion PharmacyBioMatrix Infusion Pharmacy is a trusted, independent specialty infusion pharmacy with decades of experience